Literature DB >> 20391435

Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4.

Seng-Ryong Woo1, Nianyu Li, Tullia C Bruno, Karen Forbes, Scott Brown, Creg Workman, Charles G Drake, Dario A A Vignali.   

Abstract

CD4 binds to MHC class II molecules and enhances T-cell activation. The CD4-related transmembrane protein LAG-3 (lymphocyte activation gene-3, CD223) binds to the same ligand but inhibits T-cell proliferation. We have previously shown that LAG-3 cell surface expression is tightly regulated by extracellular cleavage in order to regulate its potent inhibitory activity. Given this observation and the contrasting functions of CD4 and LAG-3, we investigated the cell distribution, location and transport of these related cell surface molecules. As expected, the vast majority of CD4 is expressed at the cell surface with minimal intracellular localization, as determined by flow cytometry, immunoblotting and confocal microscopy. In contrast, nearly half the cellular content of LAG-3 is retained in intracellular compartments. This significant intracellular storage of LAG-3 appears to facilitate its rapid translocation to the cell surface following T-cell activation, which was much faster for LAG-3 than CD4. Increased vesicular pH inhibited translocation of both CD4 and LAG-3 to the plasma membrane. While some colocalization of the microtubule organizing center, early/recycling endosomes and secretory lysosomes was observed with CD4, significantly greater colocalization was observed with LAG-3. Analysis of CD4:LAG-3 chimeras suggested that multiple domains may contribute to intracellular retention of LAG-3. Thus, in contrast with CD4, the substantial intracellular storage of LAG-3 and its close association with the microtubule organizing center and recycling endosomes may facilitate its rapid translocation to the cell surface during T-cell activation and help to mitigate T-cell activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20391435      PMCID: PMC2987677          DOI: 10.1002/eji.200939874

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  28 in total

1.  Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.

Authors:  B Huard; P Gaulard; F Faure; T Hercend; F Triebel
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

2.  Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements.

Authors:  M J Barnden; J Allison; W R Heath; F R Carbone
Journal:  Immunol Cell Biol       Date:  1998-02       Impact factor: 5.126

3.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.

Authors:  P S Linsley; J Bradshaw; J Greene; R Peach; K L Bennett; R S Mittler
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

4.  Genomic organization of the human LAG-3/CD4 locus.

Authors:  D Bruniquel; N Borie; F Triebel
Journal:  Immunogenetics       Date:  1997       Impact factor: 2.846

Review 5.  Endocytic and exocytic regulation of CD4 expression and function.

Authors:  M Marsh; A Pelchen-Matthews
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

6.  Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).

Authors:  Creg J Workman; Dario A A Vignali
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

7.  Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223).

Authors:  Nianyu Li; Creg J Workman; Stefani M Martin; Dario A A Vignali
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

8.  Regulation of surface and intracellular expression of CTLA4 on mouse T cells.

Authors:  M L Alegre; P J Noel; B J Eisfelder; E Chuang; M R Clark; S L Reiner; C B Thompson
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

9.  Independent modes of natural killing distinguished in mice lacking Lag3.

Authors:  T Miyazaki; A Dierich; C Benoist; D Mathis
Journal:  Science       Date:  1996-04-19       Impact factor: 47.728

10.  Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor.

Authors:  D A Vignali; J L Strominger
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more
  25 in total

1.  Memory CD4+ T-cell-mediated protection depends on secondary effectors that are distinct from and superior to primary effectors.

Authors:  Tara M Strutt; K Kai McKinstry; Yi Kuang; Linda M Bradley; Susan L Swain
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

2.  Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.

Authors:  Xiaobo Mao; Michael Tianhao Ou; Senthilkumar S Karuppagounder; Tae-In Kam; Xiling Yin; Yulan Xiong; Preston Ge; George Essien Umanah; Saurav Brahmachari; Joo-Ho Shin; Ho Chul Kang; Jianmin Zhang; Jinchong Xu; Rong Chen; Hyejin Park; Shaida A Andrabi; Sung Ung Kang; Rafaella Araújo Gonçalves; Yu Liang; Shu Zhang; Chen Qi; Sharon Lam; James A Keiler; Joel Tyson; Donghoon Kim; Nikhil Panicker; Seung Pil Yun; Creg J Workman; Dario A A Vignali; Valina L Dawson; Han Seok Ko; Ted M Dawson
Journal:  Science       Date:  2016-09-30       Impact factor: 47.728

3.  Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Authors:  Seng-Ryong Woo; Meghan E Turnis; Monica V Goldberg; Jaishree Bankoti; Mark Selby; Christopher J Nirschl; Matthew L Bettini; David M Gravano; Peter Vogel; Chih Long Liu; Stephanie Tangsombatvisit; Joseph F Grosso; George Netto; Matthew P Smeltzer; Alcides Chaux; Paul J Utz; Creg J Workman; Drew M Pardoll; Alan J Korman; Charles G Drake; Dario A A Vignali
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

Review 4.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

5.  Lymphocyte activation gene 3 and coronary artery disease.

Authors:  Diana Golden; Antonina Kolmakova; Sunitha Sura; Anthony T Vella; Ani Manichaikul; Xin-Qun Wang; Suzette J Bielinski; Kent D Taylor; Yii-Der Ida Chen; Stephen S Rich; Annabelle Rodriguez
Journal:  JCI Insight       Date:  2016-10-20

Review 6.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 7.  LAG-3 in Cancer Immunotherapy.

Authors:  Monica V Goldberg; Charles G Drake
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

8.  Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells.

Authors:  Theodore Kouo; Lanqing Huang; Alexandra B Pucsek; Minwei Cao; Sara Solt; Todd Armstrong; Elizabeth Jaffee
Journal:  Cancer Immunol Res       Date:  2015-02-17       Impact factor: 11.151

Review 9.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

10.  LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.

Authors:  Kevin D Cook; Jason K Whitmire
Journal:  J Immunol       Date:  2016-05-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.